Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced the pricing of its Initial Public Offering (IPO). The company is offering 1,250,000 ordinary shares at $8.00 per share, aiming to raise $10 million in gross proceeds.
The company has granted underwriters a 45-day option to purchase up to 187,500 additional shares. Trading will commence on NYSE American LLC on August 13, 2025, under the symbol "NSRX". The proceeds will primarily fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies.
Nasus Pharma (NYSE:NSRX), una società farmaceutica in fase clinica specializzata in trattamenti medici d'emergenza per somministrazione intranasale, ha annunciato il pricing della sua Offerta Pubblica Iniziale (IPO). La società offre 1,250,000 azioni ordinarie a $8.00 per azione, con l'obiettivo di raccogliere $10 million di proventi lordi.
La società ha concesso agli underwriter un'opzione di 45 giorni per acquistare fino a 187,500 azioni aggiuntive. Le negoziazioni avranno inizio su NYSE American LLC il 13 agosto 2025, con il simbolo "NSRX". I proventi saranno impiegati principalmente per finanziare lo sviluppo del programma di epinefrina intranasale, inclusi il potenziamento della produzione e gli studi di Fase 2.
Nasus Pharma (NYSE:NSRX), una compañía farmacéutica en fase clínica especializada en tratamientos médicos de emergencia por vía intranasal, ha anunciado el precio de su Oferta Pública Inicial (IPO). La compañía ofrece 1,250,000 acciones ordinarias a $8.00 por acción, con el objetivo de recaudar $10 million en ingresos brutos.
La compañía ha otorgado a los colocadores una opción de 45 días para comprar hasta 187,500 acciones adicionales. La cotización comenzará en NYSE American LLC el 13 de agosto de 2025, bajo el símbolo "NSRX". Los ingresos se destinarán principalmente al desarrollo de su programa de epinefrina intranasal, incluida la ampliación de la fabricación y los ensayos de Fase 2.
Nasus Pharma (NYSE:NSRX)는 비강 투여 응급 의료 치료를 전문으로 하는 임상 단계 제약사로서 기업공개(IPO) 공모가를 발표했습니다. 회사는 1,250,000주 보통주를 주당 $8.00에 공모해 총 $10 million의 총수익을 확보하는 것을 목표로 합니다.
회사 측은 인수인들에게 45일간 최대 187,500주 추가 인수 옵션을 부여했습니다. 거래는 2025년 8월 13일 NYSE American LLC에서 "NSRX" 심볼로 시작됩니다. 수익금은 주로 비강 투여 에피네프린 프로그램의 개발(생산 확대 및 2상 연구 포함)에 사용될 예정입니다.
Nasus Pharma (NYSE:NSRX), une société pharmaceutique en phase clinique spécialisée dans les traitements d'urgence par voie intranasale, a annoncé le prix de son Offre Publique Initiale (IPO). La société propose 1 250 000 actions ordinaires à $8.00 par action, visant à lever $10 million de produit brut.
La société a accordé aux souscripteurs une option de 45 jours pour acheter jusqu'à 187 500 actions supplémentaires. Les négociations débuteront sur NYSE American LLC le 13 août 2025, sous le symbole "NSRX". Les fonds seront principalement affectés au développement de leur programme d'épinéphrine intranasale, y compris l'augmentation de la production et les études de phase 2.
Nasus Pharma (NYSE:NSRX), ein pharmazeutisches Unternehmen in klinischer Phase, das sich auf intranasale Notfallbehandlungen spezialisiert hat, hat die Preisfestsetzung seines Börsengangs (IPO) bekannt gegeben. Das Unternehmen bietet 1.250.000 Stammaktien zu je $8.00 an und beabsichtigt, $10 million an Bruttoerlösen zu erzielen.
Das Unternehmen hat den Underwritern eine 45-tägige Option eingeräumt, bis zu 187.500 zusätzliche Aktien zu erwerben. Der Handel beginnt am 13. August 2025 an der NYSE American LLC unter dem Kürzel "NSRX". Die Erlöse sollen vorrangig die Entwicklung des intranasalen Epinephrin-Programms finanzieren, einschließlich Produktionshochlauf und Phase-2-Studien.
- None.
- Relatively small IPO size of $10 million may limit growth potential
- Clinical-stage company with no commercial products yet
- Potential dilution for future shareholders through additional share offerings
Insights
Nasus Pharma's $10M IPO provides modest funding for its intranasal emergency medication pipeline, particularly its Epinephrine program.
Nasus Pharma has priced its IPO at
This is a relatively small IPO by pharmaceutical industry standards, indicating a focused capital raise rather than a major market entry. The
Nasus specializes in developing intranasal delivery systems for emergency medical conditions, with their Epinephrine program likely targeting conditions like anaphylaxis where rapid administration is critical. The intranasal route offers potential advantages over traditional injectable epinephrine in emergency situations through easier administration and potentially faster onset.
The IPO structure with joint bookrunners Laidlaw & Company and Craft Capital Management suggests a targeted offering aimed at specialized biotech investors rather than broad market participation. The company's NYSE American listing (rather than Nasdaq) aligns with its early clinical-stage status and modest capitalization.
This capital infusion should provide Nasus with sufficient resources to reach its next clinical development milestones, though additional funding rounds will likely be necessary before commercialization of any products.
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the pricing of its initial public offering of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of
The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the remainder for general and administrative corporate purposes, including working capital, and capital expenditures.
In connection with the offering, Nasus Pharma’s Ordinary Shares have been approved for listing on the NYSE American LLC. The Ordinary Shares are expected to begin trading on the NYSE American LLC on August 13, 2025 under the ticker symbol "NSRX". The offering is expected to close on August 14, 2025, subject to customary closing conditions.
Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC are acting as Joint Bookrunners for the offering.
A registration statement on Form F-1 (File No. 333-288582) (the “Registration Statement”) relating to the initial public offering was filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC on August 12, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities referred to herein nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus forming a part of the Registration Statement. A copy of the final prospectus relating to this offering, when available, will be filed with the SEC and may also be obtained from Laidlaw & Company (UK) Ltd., 521 Fifth Ave, 12th Floor, New York, NY 10075, or by calling 212-953-4900 or by emailing syndicate@laidlawltd.com.
About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.
Forward Looking Statements
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things, statements related to the initial public offering, the expected use of proceeds from such offering, the expected start of trading of the Company’s ordinary shares on the NYSE American and the expected closing date of the offering. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Registration Statement final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Contact
info@nasuspharma.com
Nasus Pharma Ltd. Israel
https://www.nasuspharma.com
Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
FAQ
What is the IPO price for Nasus Pharma (NSRX) shares?
When will NSRX stock begin trading on the NYSE American?
How will Nasus Pharma use the IPO proceeds?
Who are the underwriters for the Nasus Pharma IPO?
What is Nasus Pharma's main business focus?
